Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals

This study explores whether switching to injectable long-acting antiretroviral therapy (HIV medications given as shots every 1–2 months instead of daily pills) improves viral suppression and treatment adherence in people living with HIV who have had trouble keeping their virus under control with oral medications. **You may be eligible if...** - You are 18 or older and have been diagnosed with HIV for at least 12 months - Your most recent viral load is 200 copies/mL or more (meaning the virus is not well-controlled) - You have been on oral HIV treatment (even if irregularly) - You weigh at least 35 kg - You are willing to receive injections in the buttocks and maintain contact with the research team **You may NOT be eligible if...** - You have been on oral HIV treatment for less than 6 consecutive months before joining - Your virus is known to be resistant to the injectable medications (cabotegravir or rilpivirine) - You are unable or unwilling to maintain contact with the research team or follow up as required Talk to your doctor to see if this trial is right for you.